AMR Centre
Infex Therapeutics is a UK-based clinical-stage biopharmaceutical company developing first-in-class anti-infective and anti-virulence drugs, including RESP-X and MET-X, to treat drug-resistant and pandemic infections, out-licensing regional rights to pharmaceutical partners such as Venus Remedies.
- Company typePrivate
- Founded2016
- HeadquartersAlderley Park, United Kingdom
- Headcount11–50
- GTM typeB2B
- OfferingServices
What AMR Centre does
Infex Therapeutics Ltd (also known as InfexTx, and previously associated with the AMR Centre brand founded in 2016) is a UK-based clinical-stage biopharmaceutical company headquartered at Alderley Park in the North West of England. The company acquires, develops, and licences innovative drugs targeting pandemic infections and antimicrobial-resistant pathogens, with a particular emphasis on first-in-class anti-virulence therapeutics — drugs designed to neutralise bacterial virulence factors rather than kill bacteria directly, in order to reduce selective pressure for resistance. Headcount is in the 11–50 range and the company is privately held.
The pipeline centres on two named candidates: RESP-X (INFEX702), a first-in-class anti-virulence antibody drug in development for non-cystic fibrosis bronchiectasis patients colonised with Pseudomonas aeruginosa, which reported positive Phase IIa dose-ranging results in May 2026; and MET-X, an antimicrobial candidate targeting multi-drug-resistant pathogens that has been exclusively licensed to Venus Remedies Ltd for the Indian market. A joint £1 million PACE grant with Justus-Liebig-University Giessen (February 2025) supports an additional first-in-class antimicrobial programme, and a Memorandum of Understanding with the Asian clinical trials network ADVANCE-ID (May 2025) extends clinical development activity into Asia.
The business model is asset-light and partnership-driven: the company does not commercialise directly but instead out-licences regional or programme rights to pharmaceutical partners (e.g., Venus Remedies in India) and supplements R&D funding through grant programmes (e.g., PACE) and equity investment, including a £4.3 million round led by Jon Moulton announced May 2026. Customer segments therefore comprise healthcare providers and health systems treating drug-resistant infections (downstream) and pharmaceutical partners/government health agencies (upstream counterparties), with revenue mechanics expected to combine upfront payments, development milestones, and royalties on eventual commercialisation.
AMR Centre firmographics
Firmographics- Name
- AMR Centre
- Legal name
- Infex Therapeutics Ltd.
- Website
- https://amrcentre.com
- Company type
- Private
- Founded year
- 2016
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Infex Therapeutics is a UK-based clinical-stage biopharmaceutical company developing first-in-class anti-infective and anti-virulence drugs, including RESP-X and MET-X, to treat drug-resistant and pandemic infections, out-licensing regional rights to pharmaceutical partners such as Venus Remedies.
- Ownership category
- akta.pro rank
AMR Centre industry classification
Industry- Product category
- Anti-infective Therapeutics
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Research and Development in Biotechnology (except Nanobiotechnology) (541714), In-Vitro Diagnostic Substance Manufacturing (325413)
- SIC
- Pharmaceutical Preparations (2834), In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071)
- akta.pro primary industry
- Infectious Disease & Antimicrobials Pharmaceuticals (HLAIAAAG)
- akta.pro secondary industries
- Microbiology & Infectious Disease Diagnostics (culture, rapid antigen, syndromic panels) (HLAAALAC), Infectious Disease & STI Testing-to-Treatment with eRx + Pharmacy Fulfillment (HLALAIAL)
Keywords
Where AMR Centre is headquartered
LocationHeadquarters
- HQ city
- Alderley Park
- HQ country
- United Kingdom
- HQ region
- Europe
Offices1 record
Markets served
AMR Centre business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales
Revenue model
- Drug Licensing and Commercialization: Infex Therapeutics acquires, develops, and licenses innovative drugs to treat pandemic infections. The company generates revenue through licensing agreements with pharmaceutical partners for development and commercialization rights to their drug candidates.
- Research Grants: The company receives grant funding for specific research programs, such as the £1 million PACE grant awarded in collaboration with Justus-Liebig-University Giessen for developing first-in-class antimicrobial drugs targeting multi-drug-resistant pathogens.
- Equity Investment: Investment from venture capital and investors such as Jon Moulton to support progression of clinical and preclinical programmes addressing critical-priority pathogens.
Go-to-market motion1 record
Distribution channels2 records
Marketing channels4 records
AMR Centre product offering
Product offeringCore offering
AMR Centre (operating through Infex Therapeutics) is a biopharmaceutical R&D organization that acquires, develops, and licenses innovative anti-infective drug candidates to address antimicrobial resistance and pandemic infections. The company advances a portfolio of anti-virulence and antimicrobial therapeutics — including RESP-X (INFEX702) for non-cystic fibrosis bronchiectasis and MET-X for multi-drug-resistant pathogens — through clinical development and partnership with global pharmaceutical companies for commercialization.
Product overview
Infex Therapeutics is a biotech company developing a portfolio of innovative anti-infective drugs to treat pandemic infections and antimicrobial-resistant pathogens. The company's pipeline includes RESP-X (INFEX702), a first-in-class anti-virulence therapy in Phase IIa trials for non-cystic fibrosis bronchiectasis, and MET-X, an antimicrobial candidate targeting multi-drug-resistant infections licensed to Venus Remedies for India. The company operates from Alderley Park and collaborates with academic institutions and clinical networks globally to advance its drug candidates through clinical development.
Differentiator
Problem solved
Functional benefit
Products and services
- RESP-X (INFEX702) First-in-class anti-virulence antibody drug candidate in clinical development for the treatment of non-cystic fibrosis bronchiectasis (NCFB) patients colonised with Pseudomonas aeruginosa. Aims to reduce the frequency of exacerbations by targeting bacterial virulence factors rather than killing bacteria directly, positioning the product for license to pharmaceutical partners for global commercialization.
- MET-X Antimicrobial drug candidate targeting multi-drug-resistant pathogens, being advanced through clinical development under an exclusive license agreement with Venus Remedies Ltd for the Indian market. Developed as part of AMR Centre's anti-infective portfolio addressing critical-priority pathogens.
Quantifiable outcome
- Positive Phase IIa dose-ranging study results for RESP-X in non-cystic fibrosis bronchiectasis patients colonised with Pseudomonas aeruginosa
Companies that use AMR Centre
Customer profileSegments2 records
Ideal customer profiles3 records
AMR Centre technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature2 records
AMR Centre partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core.
- ADVANCE-ID (Asian Clinical Trials Network)coreMemorandum of Understanding signed to investigate hospital-acquired drug-resistant infections. This collaboration supports the company's expansion into Asian markets for clinical development of anti-infective therapeutics.
- Venus Remedies LtdcoreExclusive license agreement signed to advance MET-X through clinical development and commercialisation in India. Venus Remedies Ltd gains rights to develop and commercialize the antimicrobial drug candidate in the Indian market.
- Justus-Liebig-University GiessencoreAwarded £1 million grant from PACE to develop first-in-class antimicrobial drug targeting multi-drug-resistant pathogens. Joint research collaboration combining academic expertise with pharmaceutical development capabilities.
Scale indicators4 records
Recent moves6 records
Expansion highlights6 records
AMR Centre competitors and assessment
Company assessmentDirect peers
- Antabio: Antabio is a French clinical-stage anti-infectives biotech developing novel treatments for drug-resistant bacterial infections and AMR — directly comparable to Infex's focus on first-in-class antimicrobial candidates.
- Entasis Therapeutics: Entasis (acquired by Innoviva) developed targeted anti-infective therapies for drug-resistant infections including hospital-acquired pathogens — closely aligned with Infex's AMR pipeline strategy.
- BioVersys: BioVersys is a Swiss clinical-stage biotech developing small-molecule anti-infectives targeting AMR — comparable to Infex's therapeutic anti-infective approach and pipeline stage.
- Iterum Therapeutics: Iterum is a US-listed anti-infectives biotech developing antibiotics against multi-drug-resistant pathogens — similar therapeutic focus and clinical-stage profile to Infex.
- Melinta Therapeutics: Melinta (now a Markforged-owned antibiotics business) developed and commercialised antibiotics for drug-resistant infections — a comparable anti-infectives specialist, illustrating both the opportunity and the historic commercial challenges in the space.
- VenatoRx Pharmaceuticals: VenatoRx is a US-based clinical-stage anti-infectives developer with programmes targeting resistant Gram-negative bacteria — directly comparable therapeutic area and pipeline stage.
- Nabriva Therapeutics: Nabriva is a clinical-stage anti-infectives company developing antibiotics for resistant pathogens — directly comparable to Infex's anti-infectives pipeline focus.
- Tetraphase Biosciences: Tetraphase developed tetracycline-derived antibiotics for serious and drug-resistant infections before being acquired by La Jolla Pharmaceutical — a relevant historical peer demonstrating both the value creation and the commercial fragility of the anti-infectives space.
- Cidara Therapeutics: Cidara develops antiviral and anti-infective therapeutics, including immunotherapies against infectious diseases — overlaps with Infex's infectious-disease therapeutic focus, though Cidara also has an antifungal platform.
Others
- Achaogen: Achaogen was a US anti-infectives biotech that brought plazomicin to market but ultimately filed for bankruptcy due to weak antibiotic commercial economics — a cautionary historical peer highlighting commercial risks for Infex.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
AMR Centre social profiles
Digital presenceAMR Centre financial estimates
Financial estimateRevenue estimate
Valuation estimate
AMR Centre leadership team
Management profileNumber of profiles
Profiles5 records
AMR Centre funding detail
Funding detailFunding overview
Funding rounds2 records
Investors4 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
AMR Centre M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about AMR Centre
What does AMR Centre do?
AMR Centre (operating through Infex Therapeutics) is a biopharmaceutical R&D organization that acquires, develops, and licenses innovative anti-infective drug candidates to address antimicrobial resistance and pandemic infections. The company advances a portfolio of anti-virulence and antimicrobial therapeutics — including RESP-X (INFEX702) for non-cystic fibrosis bronchiectasis and MET-X for multi-drug-resistant pathogens — through clinical development and partnership with global pharmaceutical companies for commercialization.
Is AMR Centre a public or private company?
AMR Centre is a private company. It is classified as venture growth investor backed and is currently operating.
When was AMR Centre founded?
AMR Centre was founded in 2016. It employs 11 to 50 people.
Where is AMR Centre based?
AMR Centre is headquartered in Alderley Park, United Kingdom, in the Europe region.
How does AMR Centre make money?
Three revenue lines are on record. Drug Licensing and Commercialization is the primary driver. The others are research Grants and equity Investment.
Who are AMR Centre's main competitors?
Direct peers on record are Antabio, Entasis Therapeutics, BioVersys, Iterum Therapeutics, Melinta Therapeutics, VenatoRx Pharmaceuticals, Nabriva Therapeutics, Tetraphase Biosciences and Cidara Therapeutics. Achaogen is listed as an others.
Does AMR Centre have an API?
No public API is recorded for AMR Centre.
What industry is AMR Centre in?
AMR Centre's product category is Anti-infective Therapeutics. Its primary akta.pro industry code is HLAIAAAG, Infectious Disease & Antimicrobials Pharmaceuticals, with a secondary code of HLAAALAC, Microbiology & Infectious Disease Diagnostics (culture, rapid antigen, syndromic panels). Its NAICS code is 325412 and its SIC code is 2834.